Sitaxsentan: A selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 1, 2007, Pages 95-109

  Barst, Robyn J ^a,b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b Department of Pediatrics in Medicine   (United States)

Author keywords

Endothelin receptor antagonist; Endothelin 1; Pulmonary arterial hypertension

Indexed keywords

AMINOTRANSFERASE; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DIGITALIS; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; HEMOGLOBIN; ILOPROST; LIVER ENZYME; OXYGEN; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; UNIPROST; WARFARIN;

AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULATION; ARTICLE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DEATH; DISEASE ASSOCIATION; DIZZINESS; DRUG ACCUMULATION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; ENZYME INHIBITION; EXERCISE; FUNCTIONAL STATUS; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INJECTION SITE PAIN; INJECTION SITE REACTION; INSOMNIA; LIVER FUNCTION TEST; LUNG FUNCTION TEST; MULTIPLE DRUG DOSE; NAUSEA; NOSE CONGESTION; OXYGEN CONSUMPTION; OXYGEN THERAPY; PERIPHERAL EDEMA; PROTHROMBIN TIME; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; SCLERODERMA; SIDE EFFECT; SINGLE DRUG DOSE; TOXIC HEPATITIS; UPPER RESPIRATORY TRACT INFECTION; VASODILATATION;

HUMANS; HYPERTENSION, PULMONARY; ISOXAZOLES; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, ENDOTHELIN A; THIOPHENES;

EID: 33846083957     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.1.95     Document Type: Article

References (49)

1. RICH S: Executive Summary from the World Symposium on Primary Pulmonary Hypertension. World Health Organization, Evian, France (6 - 10 September 1998).
2. RICH S, DANTZKER DR, AYRES SM et al.: Primary pulmonary hypertension: a national prospective study. Ann. Intern. Med. (1987) 107(2):216-223.
3. RUBIN LJ: Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 126(1 Suppl.):7S-10S.
4. RUBIN LJ: Primary pulmonary hypertension. N. Engl. J. Med. (1997) 336(2):111-117.
5. DENG Z, MORSE JH, SLAGER SL. et al.: Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am. J. Hum. Genet. (2000) 67(3):737-744.
6. HUMBERT M, NUNES H, SITBON O, PARENT F, HERVE P, SIMONNEAU G: Risk factors for pulmonary arterial hypertension. Clin. Chest Med. (2001) 22(3):459-475.
7. SPEICH R, JENNI R, OPRAVIL M, PFAB M, RUSSI EW. Primary pulmonary hypertension in HIV infection. Chest (1991) 100(5):1268-1271.
8. KOH ET, LEE P, GLADMAN DD, ABU-SHAKRA M: Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br. J. Rheumatol. (1996) 35(10):989-993.
9. STUPI AM, STEEN VD, OWENS GR, BARNES EL, RODNAN GP, MEDSGER TA Jr: Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum. (1986) 29(4):515-524.
10. UNGERER RG, TASHKIN DP. FURST D et al.: Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am. J. Med (1983) 75(1):65-74.
11. PRAKASH UB: Respiratory complications in mixed connective tissue disease. Clin. Chest Med (1998) 19(4):733-746.
12. RICH S, KAUFMANN E, LEVY PS: The effect of high doses of calcium-channel blockers; on survival in primary pulmonary hypertension. N. Engl. J. Med. (1992) 327(2):76-81.
13. YUNG D, WIDLITZ AC, ROSENZWEIG EB, KERSTEIN D, MAISLIN G, BARST RJ: Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation (2004) 110(6):660-665.
14. BARST RJ, RUBIN LJ, LONG WA et al.: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. (1996) 334(5):296-302.
15. BADESCH DB, TAPSON VF, MCGOON MD et al.: Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann. Intern. Med. (2000) 132(6):425-434.
16. SIMONNEAU G, BARST RJ, GALIE N et al.: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. (2002) 165(6):800-804.
17. GOMBERG-MAITLAND M, TAPSON VF et al.: Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am. J. Respir. Crit. Care Med (2005) 172(12):1586-1589.
18. TAPSON VF, GOMBERG-MAITLAND M, MCLAUGHLIN VV et al.: Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest. (2006) 129(3):683-688.
19. OLSCHEWSKI H, SIMONNEAU G, GALIE N et al.: Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. (2002) 347(5):322-329.
20. BARST RJ, IVY D, DINGEMANSE J et al.: Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin. Pharmacol. Ther. (2003) 73(4):372-382.
21. CHANNICK RN, SIMONNEAU G, SITBON O et al.: Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (2001) 358(9288):1119-1123.
22. RUBIN LJ, BADESCH DB, BARST RJ et al.: Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. (2002) 346(12):896-903.
23. GALIE N, GHOFRANI HA, TORBICKI A et al.: Sildenafil c itrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. (2005) 353(20):2148-2157.
24. MOTTE S, MCENTEE K, NAEIJE R: Endothelin receptor antagonists. Pharmacol. Ther. (2006) 100:386-414.
25. YANAGISAWA M, KURIHARA H, KIMURA S et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (1988) 332(6163):411-415.
26. D'ORLEANS-JUSTE P, LABONTE J, BKAILY C, CHOUFANI S, PLANTE M, HONORE JC: Function of the endothelin(B) receptor in cardiovascular physiology and pathophysiology. Pharmacol. Ther. (2002) 95(3):221-238.
27. JEFFERY TK, WANSTALL JC: Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol. Ther. (2001) 92(1):1-20.
28. JOANNIDES R, HAEFELI WE, LINDER L et al.: Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. (1995) 91(5):1314-1319.
29. BOHM F, PERNOW J, LINDSTROM J, AHLBORG G: ETA receptors mediate vasoconstriction, whereas ETB receptors clear endothelin-1 in the splanchnic and renal circulation of healthy men. Clin. Sci. (2003) 104(2):143-151.
30. KEDZIERSKI RM, YANAGISAWA M: Endothelin system: the double-edged sword in health and disease. Ann. Rev Pharmacol. Toxicol. (2001) 41:851-876.
31. DUPUIS J, JASMIN JF, PRIE S, CERNACEK P: Importance of local production of endothelin-1 and of the ET(B)Receptor in the regulation of pulmonary vascular tone. Pulm. Pharmacol, Ther. (2000) 13(3):135-140.
32. MCCULLOCH KM, DOCHERTY C, MACLEAN MR: Endothelin receptors mediating contraction of rat and human pulmonary resistance arteries: effect of chronic hypoxia in the rat. Br. J. Pharmacol. (1998) 123(8):1621-1630.
33. ABRAHAM DJ, VANCHEESWARAN R, DASHWOOD MR et al.: Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am. J. Pathol. (1997) 151(3):831-841.
34. MCCULLOCH KM, MACLEAN MR: EndothelinB receptor-mediated contraction of human and rat pulmonary resistance arteries and the effect of pulmonary hypertension on endothelin responses in the rat. J. Cardiovasc. Pharmacol, (1995) 26(Suppl. 3):S169-S76.
35. BAUER M, WILKENS H, LANGER F, SCHNEIDER SO, LAUSBERG H, SCHAFERS HJ: Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation (2002) 105(9):1034-1036.
36. WU C, CHAN MF, STAVROS F et al.: Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J. Med. Chem. (1997) 40(11):1690-1697.
37. O'CALLAGHAN DS, GAINE SP: Sitaxsentan: an endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension. Int. J. Clin. Pract. (2006) 60(4):475-481.
38. BARST RJ, RICH S, WIDLITZ A, HORN EM, MCLAUGHLIN V, MCFARLIN J: Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest (2002) 121(6):1860-1868.
39. BARST RJ, LANGLEBEN D, FROST A et al FOR THE STRIDE-1 STUDY GROUP: Sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care. Med. (2004) 169:441-447.
40. FROST AF, LANGLEBEN D, OUDIZ R et al.: The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. Vascul Pharmacol. (2005) 43(1):36-39.
41. OUDIZ RJ, BARST RJ, HANSEN JE et al.: Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension. Am. J. Cardiol. (2006) 97(1):123-126.
42. BARST RJ, MCGOON M, MCLAUGHLIN V et al.: Beraprost therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2003) 41(12):2119-2125.
43. LANGLEBEN D, BROCK T, DIXON R, BARST R: STRIDE 1: effects of the Selective ETA receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials. J. Cardiovasc. Pharmacol. (2004) 44:S80-S84.
44. MCLAUGHLIN VV, HILL N, TAPSON V et al.: Sitaxsentan improves 6MW in patients with pulmonary arterial hypertension (PAH) related to connective-tissue diseases (CTD). Chest (2004) 126(4 Suppl.):759S.
45. BARST RJ, LANGLEBFN D, BADESCH D et al.; STRIDE-2 STUDY GROUP: Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J. Am. Coll. Cardiol. (2006) 47(10):2049-2056.
46. PULIDO T, KURZYNA M, SOUZA R, RAMIREZ A, SANDOVAL J, INVESTIGATORS FS: Sitaxsentan 100 mg proves more effective than sitaxsentan 50 mg in patients with pulmonary arterial hypertension (PAH). Proceedings of the American Thoracic Society 2006 International Conference. San Diego, CA (2006) A417.
47. BENZA RL, KEOGH A, IVY DD, SANDOVAL J, BARST RJ: Sitaxsentan Improves Six Minute Walk Distance in Patients with Pulmonary Arterial Hypertension Related to Congenital Heart Defects. 26th ISHLT Annual Meeting and Scientific Sessions 2006 Madrid, Spain (2006):94.
48. BENZA RL, MEHTA,S, KOEGH A et al.: Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J. Heart Lung Transplant. In press.
49. BENZA RL, MEHTA S, KOEGH A et al.: Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan treatment due to lack of efficacy. European Society of Cardiology Congress 2005. Stockholm, Sweden (3 - 7 September 2005):596.